Menactra Approval Awaits Final Manufacturing Clearance

Sanofi-Aventis says it is prepared to produce a limited supply of the meningococcal conjugate vaccine soon after licensure. To meet expanded demand, the company is constructing a new Menactra manufacturing facility that will be fully operational in two to three years.